XORTX Therapeutics Archives - The Canadian Business Quarterly

XORTX Therapeutics

Featured image XORTX - Dr. Allen Davidoff, President and CEO

XORTX Therapeutics (FRA:ANU1 | CSE:XRX | OTCQB:XRTXF): Redefining kidney disease treatment

August 18, 2020 / The Canadian Business Quarterly

A publicly-listed biopharmaceutical company with three clinically advanced products in development, XORTX Therapeutics’ focus is on developing drugs for kidney disease treatment, an area where there is a large unmet

Sodexo Canada: The global leader who believes the difference a day makes

Barclay Restorations DKI: The longest running insurance restoration company in Greater Vancouver

CDW Canada: Helping small businesses use IT security to prepare, defend, and respond

Stamped Engineering Corporation: High quality, fit for purpose engineering services

Alpine Building Maintenance: Customized cleaning solutions

Case Design/Remodeling Halifax: Flawless design and execution

Weston Wood Solutions: One of Canada’s fastest growing companies

CDW Canada: Helping organizations navigate a complex IT market

Reclaiming Canada’s key service export: Tourism

Concerning signs for Canada’s construction sector in 2023

Strengthening your organization through sustainability & ESG

55% of provincial healthcare budgets will be for seniors by 2030

Spymasters, conspiracies, the PRC, & Dong Jingwei

Digital transformations on the wrong end of the stick

It’s impossible to tackle climate change without nuclear

Inflation: Demand creates its own supply

XORTX Therapeutics

XORTX Therapeutics (FRA:ANU1 | CSE:XRX | OTCQB:XRTXF): Redefining kidney disease treatment

Subscribe

Subscribe

© 2023 The Canadian Business Quarterly. All rights reserved. A division of Romulus Rising Pty Ltd, an Australian media company (www.RomulusRising.com).